{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:35:55Z","timestamp":1767792955298,"version":"3.49.0"},"reference-count":54,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01378"],"award-info":[{"award-number":["PI20\/01378"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,11,3]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>International organisations, scientists and the tuberculosis (TB) community have been advocating for a shorter, safer treatment for drug-susceptible (DS)-TB with equal or better efficacy than current regimens. A promising approach to achieve this is the combination of dose-optimised repurposed drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The RML-TB trial is a phase IIb, randomised, non-inferiority, controlled, open-label, multicentre clinical trial. It compares an experimental regimen (optimised-dose rifampicin (R) at 30mg\/kg\/day, moxifloxacin 600mg\/day and linezolid (L) 600\u2009mg\/day) with the standard fixed-dose combination regimen of R, isoniazid, pyrazinamide and ethambutol. In the experimental arm, L is administered at 600\u2009mg two times per day for 2 weeks, then once daily for 6 weeks. The primary efficacy outcome is the proportion of patients with negative culture at 8 weeks. Sputum samples will be collected at screening visit, randomisation visit and 1 week, 2 weeks, 4 weeks, 6 weeks and 8\u2009weeks post randomisation. The primary safety outcome is the incidence of grade 3\u20134 adverse events or a change in treatment regimen within 8 weeks. Safety assessment will be done using the Common Terminology Criteria for Adverse Events classification version 5. Participants must be at least 18 years old, with smear-positive, DS pulmonary TB. Exclusion criteria include corrected QT interval (QTc) prolongation, HIV positive status, severely impaired blood counts or the use of QTc-prolonging drugs. The study will enrol 120 patients (60 per arm) over a 2.5-year period across 13 TB units in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study was approved by the ethics committee from Vall d\u2019Hebron University Hospital on the meeting held on 18 March 2022 and The Spanish Drug Agency. Patients will provide informed consent and can withdraw from the trial at any time without giving any reason. This decision will not affect their medical care. Data collection is minimal, and analysis will be blinded. Personal data will be restricted to principal investigators or authorised personnel. Results will be shared via the European Union Drug Regulating Authorities Clinical Trials Database (EUDRACT) website and published in an open-source medical journal, guiding future TB clinical trials and treatment development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>EUDRACT number: 2021-001626-22. CTIS: 2023-509075-17-00.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-002475","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:56:27Z","timestamp":1765173387000},"page":"e002475","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocol"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2175-0842","authenticated-orcid":false,"given":"Laura","family":"Diab Casares","sequence":"first","affiliation":[{"name":"Clinical Microbiology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain"},{"name":"Mycobacteria Study Group, Spanish Society of Infectious Diseases and Clinical Microbiology (GEIM-SEIMC), Spain, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Espinosa Pereiro","sequence":"additional","affiliation":[{"name":"Mycobacteria Study Group, Spanish Society of Infectious Diseases and Clinical Microbiology (GEIM-SEIMC), Spain, Spain"},{"name":"Infectious Diseases Department, Hospital Universitario Vall d'Hebron, Barcelona, Catalu\u00f1a, Spain"},{"name":"Networked Biomedical Research Center for Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"T\u00f3rtola Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Mycobacteria Study Group, Spanish Society of Infectious Diseases and Clinical Microbiology (GEIM-SEIMC), Spain, Spain"},{"name":"Networked Biomedical Research Center for Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Microbiology Department, Autonomous University of Barcelona, Medicine Department, Campus Hospital Universitario Vall d'Hebron, Barcelona, Catalu\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Casas Garc\u00eda","sequence":"additional","affiliation":[{"name":"Respiratory Department, Serveis Clinics SAU, Barcelona, Catalu\u00f1a, Spain"},{"name":"Respiratory Infections Working Group of the Catalan Society of Respiratory Medicine (SOCAP), Catalu\u00f1a, Catalu\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan Pau","family":"Millet","sequence":"additional","affiliation":[{"name":"Epidemiology, Public Health Agency of Catalonia, Barcelona, Catalu\u00f1a, Spain"},{"name":"CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Pomar Solchaga","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalu\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Navas Elorza","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Troya Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario Infanta Leonor, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"D\u00edaz de Santiago","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Luque M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Andaluc\u00eda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Francisco","family":"Medina Gallardo","sequence":"additional","affiliation":[{"name":"Medical\u2013Surgical Unit for Respiratory Diseases (UMQER), Hospital Universitario Virgen del Roc\u00edo, Sevilla, Andaluc\u00eda, Spain"},{"name":"Integrated Research Program on Tuberculosis and Nontuberculous Mycobacteria (PII-TB&MNT), Spanish Society of Respiratory Medicine and Thoracic Surgery (SEPAR), Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Gonz\u00e1lez Gal\u00e1n","sequence":"additional","affiliation":[{"name":"Mycobacteria Study Group, Spanish Society of Infectious Diseases and Clinical Microbiology (GEIM-SEIMC), Spain, Spain"},{"name":"Clinical Unit of Infectious Diseases, Microbiology and Clinical Parasitology (UCEIMP), Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"},{"name":"Seville Institute of Biomedicine, Sevilla, Andaluc\u00eda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Montero Alonso","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitario y Politecnico La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gil Brusola","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitario y Politecnico La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Rabu\u00f1al Rey","sequence":"additional","affiliation":[{"name":"Mycobacteria Study Group, Spanish Society of Infectious Diseases and Clinical Microbiology (GEIM-SEIMC), Spain, Spain"},{"name":"Department of Internal Medicine, Hospital Universitario Lucus Augusti, Lugo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Anibarro Garc\u00eda","sequence":"additional","affiliation":[{"name":"Tuberculosis Unit, Infectious Diseases, Internal Medicine Department, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain"},{"name":"Immunology Research Group, Research Institute, Sanitaria Galicia Sur, Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Sanz Herrero","sequence":"additional","affiliation":[{"name":"Respiratory Department, Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remedio","family":"Guna Serrano","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain"},{"name":"Mycobacteria Study Group, Spanish Society of Infectious Diseases and Clinical Microbiology (GEIM-SEIMC), Spain, Spain"},{"name":"Clinical Microbiology Department, Faculty of Medicine, University of Valencia, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Garrig\u00f3 Fullola","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"},{"name":"Sant Pau Biomedical Research Institute, Barcelona, Catalu\u00f1a, Spain"},{"name":"Department of Genetics and Microbiology, Autonomous University of Barcelona, Barcelona, Catalu\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Tato D\u00edez","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Department, Hospital Universitario Ramon y Cajal, Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Talavan Zan\u00f3n","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Department, Hospital Universitario Infanta Leonor, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Francisca","family":"Portero","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Alonso Garc\u00eda","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Department, Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M","family":"Saez L\u00f3pez","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Department, Hospital Provincial de Pontevedra, Pontevedra, Galicia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luisa","family":"Aznar","sequence":"additional","affiliation":[{"name":"Mycobacteria Study Group, Spanish Society of Infectious Diseases and Clinical Microbiology (GEIM-SEIMC), Spain, Spain"},{"name":"Infectious Diseases Department, Hospital Universitario Vall d'Hebron, Barcelona, Catalu\u00f1a, Spain"},{"name":"Networked Biomedical Research Center for Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Mart\u00ednez Campreci\u00f3s","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitario Vall d'Hebron, Barcelona, Catalu\u00f1a, Spain"},{"name":"Networked Biomedical Research Center for Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Saborit","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitario Vall d'Hebron, Barcelona, Catalu\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2194-5447","authenticated-orcid":false,"given":"Adri\u00e1n","family":"S\u00e1nchez Montalv\u00e1","sequence":"additional","affiliation":[{"name":"Mycobacteria Study Group, Spanish Society of Infectious Diseases and Clinical Microbiology (GEIM-SEIMC), Spain, Spain"},{"name":"Infectious Diseases Department, Hospital Universitario Vall d'Hebron, Barcelona, Catalu\u00f1a, Spain"},{"name":"Networked Biomedical Research Center for Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"2026010701522656000_12.1.e002475.1","unstructured":"WHO . Global tuberculosis report. WHO; 2022."},{"key":"2026010701522656000_12.1.e002475.2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376"},{"key":"2026010701522656000_12.1.e002475.3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jinf.2017.10.007","article-title":"Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study","volume":"76","author":"Efsen","year":"2018","journal-title":"J Infect"},{"key":"2026010701522656000_12.1.e002475.4","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0391"},{"key":"2026010701522656000_12.1.e002475.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400"},{"key":"2026010701522656000_12.1.e002475.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1033-7","article-title":"Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study","volume":"16","author":"Tweed","year":"2018","journal-title":"BMC Med"},{"key":"2026010701522656000_12.1.e002475.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x"},{"key":"2026010701522656000_12.1.e002475.8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1513\/AnnalsATS.201711-885ED","article-title":"Isoniazid Monoresistance: A Precursor to Multidrug-Resistant Tuberculosis?","volume":"15","author":"O\u2019Donnell","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2026010701522656000_12.1.e002475.9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-0172"},{"key":"2026010701522656000_12.1.e002475.10","doi-asserted-by":"crossref","DOI":"10.1186\/s40249-023-01107-x","article-title":"Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Salari","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"2026010701522656000_12.1.e002475.11","unstructured":"World Health Organization . WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the who treatment guidelines for drug-resistant tuberculosis. Geneva World Health Organization; 2018. Available: https:\/\/iris.who.int\/handle\/10665\/260494"},{"key":"2026010701522656000_12.1.e002475.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"2026010701522656000_12.1.e002475.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1264OC"},{"key":"2026010701522656000_12.1.e002475.14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.cmi.2021.03.031","article-title":"Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis","volume":"27","author":"Onorato","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026010701522656000_12.1.e002475.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212537"},{"key":"2026010701522656000_12.1.e002475.16","doi-asserted-by":"crossref","unstructured":"Jindani A , Atwine D , Grint D , et al . Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis. NEJM Evid 2023;2. doi:10.1056\/EVIDoa2300054","DOI":"10.1056\/EVIDoa2300054"},{"key":"2026010701522656000_12.1.e002475.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507062"},{"key":"2026010701522656000_12.1.e002475.18","unstructured":"Manual operativo de la OMS sobre la tuberculosis . M\u00f3dulo 4: tratamiento. tratamiento de la tuberculosis farmacorresistente. actualizaci\u00f3n del 2022. 2024. Available: https:\/\/www.who.int\/es\/publications\/i\/item\/9789240065116"},{"key":"2026010701522656000_12.1.e002475.19","doi-asserted-by":"publisher","DOI":"10.1086\/521894"},{"key":"2026010701522656000_12.1.e002475.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01621-06"},{"key":"2026010701522656000_12.1.e002475.21","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0935"},{"key":"2026010701522656000_12.1.e002475.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200806-892OC"},{"key":"2026010701522656000_12.1.e002475.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"2026010701522656000_12.1.e002475.24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tube.2015.07.003","article-title":"Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates","volume":"95","author":"Zou","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"key":"2026010701522656000_12.1.e002475.25","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0451"},{"key":"2026010701522656000_12.1.e002475.26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01378-08"},{"key":"2026010701522656000_12.1.e002475.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00009509"},{"key":"2026010701522656000_12.1.e002475.28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eimc.2015.04.003","article-title":"Retrospective study of tolerability and efficacy of linezolid in patients with multidrug-resistant tuberculosis (1998-2014)","volume":"34","author":"Ram\u00edrez-Lapausa","year":"2016","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2026010701522656000_12.1.e002475.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.01.020"},{"key":"2026010701522656000_12.1.e002475.30","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010366445"},{"key":"2026010701522656000_12.1.e002475.31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jiac.2015.11.012","article-title":"Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring","volume":"22","author":"Ashizawa","year":"2016","journal-title":"J Infect Chemother"},{"key":"2026010701522656000_12.1.e002475.32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1473-3099(16)30315-2","article-title":"Finding the right dose of rifampicin, and the right dose of optimism","volume":"17","author":"Ruslami","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2026010701522656000_12.1.e002475.33","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku415"},{"key":"2026010701522656000_12.1.e002475.34","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76605","article-title":"Population-based sequencing of Mycobacterium tuberculosis reveals how current population dynamics are shaped by past epidemics","volume":"11","author":"Cancino-Mu\u00f1oz","year":"2022","journal-title":"Elife"},{"key":"2026010701522656000_12.1.e002475.35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22705-z","article-title":"Genomic analyses of Mycobacterium tuberculosis from human lung resections reveal a high frequency of polyclonal infections","volume":"12","author":"Moreno-Molina","year":"2021","journal-title":"Nat Commun"},{"key":"2026010701522656000_12.1.e002475.36","doi-asserted-by":"crossref","first-page":"e01583","DOI":"10.1128\/AAC.01583-19","article-title":"Population Pharmacokinetics and Pharmacogenetics of Ethambutol in Adult Patients Coinfected with Tuberculosis and HIV","volume":"64","author":"Sundell","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026010701522656000_12.1.e002475.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.04.019"},{"key":"2026010701522656000_12.1.e002475.38","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40262-019-00763-3","article-title":"Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis","volume":"58","author":"Saktiawati","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026010701522656000_12.1.e002475.39","doi-asserted-by":"crossref","first-page":"e00384","DOI":"10.1128\/AAC.00384-19","article-title":"Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients","volume":"63","author":"van den Elsen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026010701522656000_12.1.e002475.40","unstructured":"Tuberculosis patient cost surveys: a handbook. 2024. Available: https:\/\/www.who.int\/publications-detail-redirect\/9789241513524"},{"key":"2026010701522656000_12.1.e002475.41","unstructured":"Common terminology criteria for adverse events (CTCAE). 2017."},{"key":"2026010701522656000_12.1.e002475.42","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/cid\/ciab576","article-title":"Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment Trials","volume":"73","author":"Weir","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026010701522656000_12.1.e002475.43","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.19.0115"},{"key":"2026010701522656000_12.1.e002475.44","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0028-2023","article-title":"Treatment-shortening regimens for tuberculosis: updates and future priorities","volume":"19","author":"Saluzzo","year":"2023","journal-title":"Breathe (Sheff)"},{"key":"2026010701522656000_12.1.e002475.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.105938"},{"key":"2026010701522656000_12.1.e002475.46","first-page":"128","article-title":"A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026010701522656000_12.1.e002475.47","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw473"},{"key":"2026010701522656000_12.1.e002475.48","doi-asserted-by":"publisher","DOI":"10.2165\/11532080-000000000-00000"},{"key":"2026010701522656000_12.1.e002475.49","doi-asserted-by":"crossref","unstructured":"Srivastava S , Magombedze G , Koeuth T , et al . Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. Antimicrob Agents Chemother 2017;61. doi:10.1128\/AAC.00751-17","DOI":"10.1128\/AAC.00751-17"},{"key":"2026010701522656000_12.1.e002475.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2026010701522656000_12.1.e002475.51","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06331-8","article-title":"TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis","volume":"23","author":"Berry","year":"2022","journal-title":"Trials"},{"key":"2026010701522656000_12.1.e002475.52","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30190-6"},{"key":"2026010701522656000_12.1.e002475.53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21025-6","article-title":"In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis","volume":"12","author":"Brankin","year":"2022","journal-title":"Sci Rep"},{"key":"2026010701522656000_12.1.e002475.54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-002475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:54:24Z","timestamp":1767779664000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-002475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,7]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjresp-2024-002475"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-002475","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}